Instil Bio is a biotech company with no active drug programs after discontinuing AXN-2510; it is evaluating acquisitions and in-licensing of new drug candidates.
Instil discontinued AXN-2510, a PD-L1 and VEGF bispecific antibody licensed from ImmuneOnco, and ended the license, which left it with no active programs. It had $69.9 million in cash and marketable securities at June 30, which it expects to fund its current plan beyond 2027, and it is evaluating acquisitions and in-licensing. No new asset has been announced.
Thesis checklist
0 risks need attention
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Next decision point
Tests: Instil acquires or licenses a new asset
Does Instil acquire or license a promising new drug candidate?
Strong, inconclusive and weak outcomes
What to look for in the result and how each would move the checklist
Price and material events
Select an event marker to read the update below. Marker colors show Thesis status.
Instil Bio has no active programs after dropping AXN-2510 and is looking for a new asset
About this history: every entry shows when the Thesis moved and what it said. The reasoning behind each move (the evidence, the analysis and the source filing) and the earnings write-ups are part of a subscription.
Dates, trials and completed outcomes are open to everyone. What each upcoming milestone hinges on is part of a subscription.
Cash: Market-data provider estimate; measurement period unavailable.
Debt: Market-data provider estimate; a complete comparable filing balance is unavailable.
Quarterly burn: Estimated from trailing free cash flow; measurement period unavailable.
Net cash and estimated runway require verified matching measurement periods. Missing debt components are not assumed to be zero.
Runway: No underlying guidance available.